Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Bonomi, P. D. [1 ]
Mace, J. [1 ]
Mandanas, R. D. [1 ]
Min, M. [1 ]
Zhang, Y. [1 ]
Rowinsky, E. [1 ]
Youssoufian, H. [1 ]
机构：
[1] Rush Univ, Ctr Med, Chicago, IL 60612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8046
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer
    Soria, Jean-Charles
    Mark, Zsuzsanna
    Zatloukal, Petr
    Szima, Barna
    Albert, Istvan
    Juhasz, Erzsebet
    Pujol, Jean-Louis
    Kozielski, Jerzy
    Baker, Nigel
    Smethurst, Dominic
    Hei, Yong-jiang
    Ashkenazi, Avi
    Stern, Howard
    Amler, Lukas
    Pan, Yang
    Blackhall, Fiona
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) : 4442 - 4451
  • [22] Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
    Zinner, Ralph
    Ross, Helen J.
    Weaver, Robert
    Govindan, Ramaswamy
    Holden, Viran R.
    Chowhan, Naveed Mahfooz
    Beck, J. Thaddeus
    Waterhouse, David Michael
    Modiano, Manuel
    Rao, Vijay Phooshkooru
    Liu, Jingyi
    Koustenis, Andrew
    Melemed, Symantha
    Guba, Susan C.
    Ortuzar, Waldo Feliu
    Desaiah, Durisala
    Spigel, David R.
    Obasaju, Coleman K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [23] An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC)
    Reynolds, C.
    Barrera, D.
    Vu, D. Q.
    Jotte, R.
    Spira, A. I.
    Weissman, C. H.
    Boehm, K. A.
    Ilegbodu, D.
    Pritchard, S.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer
    Camidge, D. Ross
    Berge, Eamon M.
    Doebele, Robert C.
    Ballas, Marc S.
    Jahan, Thierry
    Haigentz, Missak, Jr.
    Hoffman, David
    Spicer, James
    West, Howard
    Lee, Pablo
    Yang, Ling
    Joshi, Adarsh
    Gao, Ling
    Yurasov, Sergey
    Mita, Alain
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (10) : 1532 - 1539
  • [25] Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).
    Semrad, Thomas John
    Redman, Mary Weber
    Herbst, Roy S.
    Kim, Edward S.
    Bazhenova, Lyudmila
    Masters, Gregory A.
    Oettel, Kurt R.
    Guaglianone, Perry
    Reynolds, Christopher M.
    Karnad, Anand B.
    Arnold, Susanne M.
    Varella-Garcia, Marileila
    Moon, James
    Mack, Philip C.
    Blanke, Charles David
    Hirsch, Fred R.
    Kelly, Karen
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Exploratory biomarker analyses from ECOG 4508: Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients (pts)
    Aggarwal, Charu
    Dahlberg, Suzanne Eleanor
    Hanna, Nasser
    Kolesar, Jill
    Hirsch, Fred R.
    Ramalingam, Suresh S.
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Phase II study of Docetaxel (D) and Carboplatin (C) combination in advanced Non-Small Cell Lung Cancer (NSCLC)
    Chowdhury, Qamruzzaman
    Begum, Ferdous A.
    Nahar, Ferdous
    Fairuz, Saima
    Faruqui, Mesba
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S673 - S673
  • [28] A Phase Ib Study to Evaluate the P13-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
    Groen, H.
    Adjei, A. A.
    Dy, G. K.
    Ware, J. A.
    Shankar, G.
    Brachmann, R. K.
    Besse, B.
    Bahleda, R. K.
    Gomez-Roca, C.
    Soria, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S595 - S595
  • [29] Phase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC)
    Bradford, D. S.
    Socinski, M. A.
    LaRocca, R. V.
    Hensing, T. A.
    Bordoni, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] A phase III, open-label, randomized study of atezolizumab in combination with carboplatin plus paclitaxel plus bevacizumab compared with pemetrexed plus cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).
    Park, Sehhoon
    Lee, Yun-Gyoo
    Park, Ji Hyun
    Lee, Gyeong-Won
    Kang, Eun Joo
    Choi, Yoon Ji
    Shin, SeongHoon
    Han, Ji-Youn
    Lee, Suee
    Kim, YuJung
    Kim, Tae Min
    Kim, Sang-We
    Shim, Byoung Yong
    Cho, Jinhyun
    Kim, Hye Sook
    Park, Sang Gon
    Lee, Ki Hyeong
    Kim, Ilhwan
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345